SCHEMBL6884532

SCHEMBL6884532

Oc1cccc(SC2CCN(CCCc3ccccc3)C2)c1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 7/20 0.55
OPRD1 P41143 3/20 0.55
OPRK1 P41145 2/20 0.55
ADRA2A P08913 1/20 0.55
AR P10275 1/20 0.55
PTGS1 P23219 1/20 0.55
SLC6A2 P23975 1/20 0.55
HTR2A P28223 1/20 0.55
ADRA1A P35348 1/20 0.55
PTGS2 P35354 1/20 0.55
SLC6A3 Q01959 1/20 0.55
KCNH2 Q12809 1/20 0.55
SCN5A Q14524 1/20 0.55
GRM5 P41594 1/20 0.49
GRIN1 Q05586 1/20 0.49
GRIN2B Q13224 1/20 0.49
SIGMAR1 Q99720 1/20 0.49
HTR7 P34969 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6875117 0.88 SIGMAR1 (0.49) OPRM1GRM5GRIN1GRIN2BSIGMAR1
Hydrochloric Acid SCHEMBL6873860 0.87 SIGMAR1 (0.48) OPRM1GRIN2BSIGMAR1
SCHEMBL6875081 0.84 SIGMAR1 (0.50) GRM5GRIN1GRIN2BSIGMAR1
SCHEMBL6874312 0.84 SIGMAR1 (0.50) GRM5GRIN1GRIN2BSIGMAR1
SCHEMBL6880262 0.84 SIGMAR1 (0.50) GRM5GRIN1GRIN2BSIGMAR1
Hydrochloric Acid SCHEMBL6884566 0.83 SIGMAR1 (0.49) GRM5GRIN1GRIN2BSIGMAR1
SCHEMBL6881131 0.81 KDM4E (0.51)
Hydrochloric Acid SCHEMBL7145978 0.80 OPRM1 (0.50) OPRM1OPRD1OPRK1GRIN1GRIN2B
SCHEMBL6876403 0.78 SIGMAR1 (0.50) GRM5GRIN1GRIN2BSIGMAR1
SCHEMBL7319550 0.75 SIGMAR1 (0.74) OPRM1OPRD1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1278728-B1 PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS HOFFMANN LA ROCHE (CH) 2004-08-25 EP disclosed
US-6451819-B2 PYRROLIDINE-3-YL-SULFANYL, OR SUFONYL OR SUFINYL DERIVATIVES USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES HOFFMANN-LA ROCHE INC. 2002-09-17 US disclosed
US-20010047031-A1 Heterocyclic compounds useful as NMDA receptor selective subtype blockers HOFFMANN-LA ROCHE INC. 2001-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010047031-A1 Heterocyclic compounds useful as NMDA receptor selective subtype blockers GRIN1, GRM1, GRIN2B OPRM1 8/4885OPRD1 75/4885OPRK1 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.